Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

MEDA Says FDA Approved Dymista - Quick Facts

MEDA AB (MDABF.PK) said the U.S. Food and Drug Administration has approved Dymista, a new patented product for treatment of seasonal allergic rhinitis, or SAR. In several clinical studies, Dymista has consistently showed a rapid and more complete symptom relief than standard treatment.

Anders Lönner, CEO of Meda AB, said, "...The approval of Dymista represents an important achievement for Meda's clinical development groups in the US and Europe. Meda's franchise in the allergy area is strengthened and gives opportunities for the company to grow and establish collaborations in the field. Dymista will be available in the US during the second half of 2012".

Click here to receive FREE breaking news email alerts for Meda AB and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.